Results 201 to 210 of about 1,632,613 (263)

Cultures as types and the utility of viable specimens for fungal nomenclature. [PDF]

IMA Fungus
Yurkov A, Visagie CM, Crous PW, Hashimoto A, Baschien C, Begerow D, Kemler M, Schoutteten N, Stadler M, Wijayawardene NN, Hyde KD, Zhang N, Boekhout T, ICTF Yeast Working Group, May TW, Thines M, Hawksworth DL.   +16 more
europepmc   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Invasive yeast infection in paediatric acute lymphoblastic leukaemia: A report from the multi-international clinical trial AIEOP-BFM ALL 2009. [PDF]

Br J Haematol
Groll AH, Cesaro S, Alten J, Attarbaschi A, Barbaric D, Ebrahimi-Fakhari D, Bodmer N, Conter V, Elitzur S, Möricke A, Schrappe M, Stary J, Zapotocka E, Zimmermann M, Lehrnbecher T.   +14 more
europepmc   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Integrated chemical and genetic authentication of Polygoni Multiflori Caulis: Refuting diameter restrictions and exposing market adulteration. [PDF]

PeerJ
Ngo NP, Lee MS, Chiang P, Huang JY, Hung HL, Wu KC.   +5 more
europepmc   +1 more source

Efficacy and safety of empagliflozin for treating neutropenia and neutrophil dysfunction in paediatric patients with glycogen storage disease type Ib: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Glycogen storage disease type Ib (GSD‐Ib) is a rare genetic disorder causing neutropenia and neutrophil dysfunction in children. G‐CSF has been the primary treatment, but emerging data support the potential of empagliflozin, an SGLT2 inhibitor, as a promising investigational option.
Elizabeth Iwasyk, Ryan Jin, Fabio Tuzzolino, Giusy Ranucci, Donatella Madonia, Alessio Provenzani   +5 more
wiley   +1 more source

The Sweetpotato Black Rot Pathogen Ceratocystis fimbriata. [PDF]

Mol Plant Pathol
Avila K, Parada-Rojas CH, Mascarenhas J, Quesada-Ocampo LM.   +3 more
europepmc   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

expowo: An R package for mining global plant diversity and distribution data. [PDF]

Appl Plant Sci
Zuanny DC, Vilela B, Moonlight PW, Särkinen TE, Cardoso D.   +4 more
europepmc   +1 more source

Colonial legacies in eponymous species names: a global network perspective

Bharadwaj A, Pick JL, Lenzner B.
europepmc   +1 more source